Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Terms of Use
Privacy Policy
Sitemap
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Non-small cell lung cancer
•
ALK+
Would you consider using ensartinib in patients with ALK positive NSCLC who have progressed on alectinib and lorlatinib?
Related Questions
Which patients with resectable Stage IB-IIIA NSCLC would most benefit from using neoadjuvant chemoimmunotherapy as per CheckMate 816?
Due to the high incidence of hyperlipidemia secondary to lorlatinib, do you provide empiric statin therapy to all patients without known contraindications upon initiation of lorlatinib?
Would you consider using sotorasib first line in patient with metastatic KRAS G12C NSCLC who declines chemotherapy?
For patients with NSCLC on osimertinib who progress, would you continue osimertinib when moving onto chemotherapy for 2nd line therapy?
Based on results from ADAURA, in clinical practice, how likely are you to recommend adjuvant chemotherapy prior to adjuvant osimertinib for stage IIA T2bN0 EGFR mutant NSCLC?
Are there best practices for managing or mitigating toxicity from sotorasib such as hyperbilirubinemia or edema?
Should IMPower010 results be extrapolated to superior sulcus tumors treated with chemoradiation and surgery?
How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?
What adjuvant therapy would you offer following adjuvant chemotherapy for a patient with Stage III lung adenocarcinoma with an atypical EGFR mutation such as EGFR L861R?
Do you hold/avoid pemetrexed in patients with NSCLC and pleural effusions?
